These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
44. Novel monoclonal antiendotoxin antibody therapy: efficacy at any price? Fant WK Pharmacoeconomics; 1993 Jun; 3(6):437-45. PubMed ID: 10146878 [No Abstract] [Full Text] [Related]
45. A model for rational introduction of new and expensive medicines. Bell E; McCartney C Postgrad Med J; 1995 Feb; 71(832):86-9. PubMed ID: 7724440 [TBL] [Abstract][Full Text] [Related]
46. Another negative clinical trial of a new agent for the treatment of sepsis: rethinking the process of developing adjuvant treatments for serious infections. Fink MP Crit Care Med; 1995 Jun; 23(6):989-91. PubMed ID: 7774236 [No Abstract] [Full Text] [Related]
48. Who should receive antiendotoxin monoclonal antibody therapy? Hardin TC; DiPiro JT Clin Pharm; 1992 Mar; 11(3):255-6. PubMed ID: 1611815 [No Abstract] [Full Text] [Related]
49. Increasing awareness of sepsis: World Sepsis Day. Vincent JL Crit Care; 2012 Sep; 16(5):152. PubMed ID: 22971299 [No Abstract] [Full Text] [Related]
50. Variation and Cost-effectiveness of Quality Measurement Programs. The Case of Sepsis Bundles. Wall MJ; Howell MD Ann Am Thorac Soc; 2015 Nov; 12(11):1597-9. PubMed ID: 26540416 [No Abstract] [Full Text] [Related]
51. The Effectiveness of NEPA. Culhane PJ Science; 1978 Dec; 202(4372):1034-6. PubMed ID: 17777937 [No Abstract] [Full Text] [Related]
52. The Effectiveness of NEPA. Liroff RA Science; 1978 Dec; 202(4372):1036-8. PubMed ID: 17777940 [No Abstract] [Full Text] [Related]
53. Novel pharmacologic approaches to the management of sepsis: targeting the host inflammatory response. Wheeler DS; Zingarelli B; Wheeler WJ; Wong HR Recent Pat Inflamm Allergy Drug Discov; 2009 Jun; 3(2):96-112. PubMed ID: 19519586 [TBL] [Abstract][Full Text] [Related]
54. The costs of septic syndromes in the intensive care unit and influence of hospital-acquired sepsis. Brun-Buisson C; Roudot-Thoraval F; Girou E; Grenier-Sennelier C; Durand-Zaleski I Intensive Care Med; 2003 Sep; 29(9):1464-71. PubMed ID: 12856120 [TBL] [Abstract][Full Text] [Related]
55. [Cost-effectiveness analysis of human monoclonal antibody HA-1A in patients with sepsis syndrome]. Van Hout BA; Rutten FF; Lorijn RH Ned Tijdschr Geneeskd; 1993 Feb; 137(7):360-4. PubMed ID: 8437635 [TBL] [Abstract][Full Text] [Related]
56. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group. Ziegler EJ; Fisher CJ; Sprung CL; Straube RC; Sadoff JC; Foulke GE; Wortel CH; Fink MP; Dellinger RP; Teng NN N Engl J Med; 1991 Feb; 324(7):429-36. PubMed ID: 1988827 [TBL] [Abstract][Full Text] [Related]
57. Cost-effectiveness of HA-1A monoclonal antibody for gram-negative sepsis. Economic assessment of a new therapeutic agent. Schulman KA; Glick HA; Rubin H; Eisenberg JM JAMA; 1991 Dec; 266(24):3466-71. PubMed ID: 1744962 [TBL] [Abstract][Full Text] [Related]
58. Gram-negative sepsis, the sepsis syndrome, and the role of antiendotoxin monoclonal antibodies. Barriere SL; Guglielmo BJ Clin Pharm; 1992 Mar; 11(3):223-35. PubMed ID: 1611812 [TBL] [Abstract][Full Text] [Related]
59. Cost-effectiveness of HA-1A treatment for patients with sepsis. van Hout BA; Birnie E; Redekop WK; Lorijn RH; Bossuyt PM; Rutten FF Prog Clin Biol Res; 1994; 388():435-43. PubMed ID: 7831376 [TBL] [Abstract][Full Text] [Related]